QuidelOrtho sees Q1 2026 revenue of $615-$620 million on weak respiratory season
QuidelOrtho preliminarily estimated first-quarter 2026 revenue at $615-$620 million, citing a weaker respiratory season, slower China distributor sales and delayed EMEA orders. The company said only the low end of its full-year 2026 guidance remains achievable, and that its guidance ranges were intentionally broad.
- Preliminary unaudited Q1 2026 revenue (quarter ended March 29, 2026) of $615-$620 million
- U.S. influenza-like illness visits were down approximately 30% versus Q1 2025, per the CDC
- Q1 2026 free cash flow expected to be $(65) to $(70) million negative; full-year free cash flow still expected to be positive
- Full first-quarter results and full-year guidance discussion scheduled for May 5, 2026